कंपनी का अवलोकन
Roivant Sciences Ltd. operates as a clinical-stage biopharmaceutical entity dedicated to the discovery, development, and commercialization of novel medicines and technologies. The company functions within the Healthcare sector, specifically inside the Biotechnology industry, which implies a focus on high-risk, high-reward research and development cycles involving novel drug candidates. As of the latest reporting period, Roivant Sciences Ltd. maintains a substantial market capitalization of $20.28 billion, supported by an annual revenue of $13.31 million and an operational workforce of 750 employees. The disparity between the company's massive market valuation of $20.28 billion and its modest revenue of $13.31 million indicates that the market price heavily anticipates future commercial success from its pipeline of clinical product candidates rather than current operational performance.
वित्तीय स्वास्थ्य
Roivant Sciences Ltd. reported a revenue of $13.31 million over the trailing twelve months, while simultaneously recording a net income of $-809,240,000 and an EBITDA of $-1,264,381,952. The significant gap between the positive revenue figure of $13.31 million and the substantial net loss reveals a cost structure where operating expenses, likely driven by clinical trial costs and research expenditures, vastly outweigh current sales generation. The company generated a free cash flow of $-334,342,944, which indicates a negative financial flexibility where cash burn continues to outpace cash generation from operations. All three margin metrics reflect this intense capital expenditure phase: the gross margin stands at 0.0%, the operating margin is -16965.3%, and the profit margin is 0.0%. The company holds $4.53 billion in cash against a debt load of $108.94 million, resulting in a debt-to-equity ratio of 2.19. Despite the high leverage indicated by the debt-to-equity ratio, the balance sheet is underpinned by significant cash reserves, suggesting a conservative approach to servicing debt obligations relative to available liquidity. The current ratio of 30.66 points to an exceptionally strong short-term liquidity position, indicating the company possesses ample current assets to cover its current liabilities. Return on Equity is -19.1% and Return on Assets is -14.5%, metrics that reveal that management is currently generating losses on both equity and asset bases as the company invests capital into its clinical-stage portfolio.
मूल्यांकन आकलन
The company presents a trailing P/E ratio of N/A due to its net losses, while the forward P/E is -27.46, a metric that implies future earnings are expected to remain negative or that the market is valuing the firm on non-earnings fundamentals. The price-to-book ratio is 4.71, indicating that the market values Roivant Sciences Ltd. at a significant premium over its book value, reflecting high expectations for the success of its pipeline assets. Valuation is further contextualized by a price-to-sales ratio of 1523.35 and an EV/EBITDA of -13.10, suggesting that investors are pricing the stock based on potential future revenue milestones rather than current profitability. The stock has traded between a 52-week high of $30.33 and a 52-week low of $8.73, establishing a wide trading range that reflects high market sentiment volatility. The beta value of 1.21 indicates that the stock price exhibits higher volatility relative to the broader market, moving more aggressively than the average equity in the healthcare sector.
Growth & Income
The company experienced a revenue growth rate of -77.8% year-over-year, while earnings growth is marked as N/A due to the company's unprofitable status. The negative revenue growth suggests a contraction in sales, whereas the lack of earnings growth data reflects the absence of positive net income to measure against prior periods. As a non-dividend payer, Roivant Sciences Ltd. maintains a dividend yield of N/A and a payout ratio of 0.0%, meaning the company reinvests all available capital and potential earnings back into research and development rather than distributing cash to shareholders. The overall growth and income profile for Roivant Sciences Ltd. is characterized by significant revenue contraction and a complete absence of dividend income, consistent with a clinical-stage biotechnology firm focused on asset accumulation rather than current shareholder returns.